Consistent with previous studies [28-30], patients harboring germline BRCA1 mutant tumors had a worse TTP (p=0.023) and shorter OS (p=0.007) to PARP inhibitor monotherapy compared to patients with germline BRCA2 mutant cancers in our series of patients. The gene discussed is BRCA1; the disease is cancer.